Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women

Fukamizu Y, Uchida Y, Shigekawa A, Sato T, Kosaka H, Sakurai T · Scientific Reports

The highest-dose human NMN safety trial: 1,250 mg/day for 4 weeks produced no severe adverse events and no changes beyond physiological variation in hematology, blood chemistry, urinalysis or body composition — the study underpinning any claim that gram-level daily NMN is tolerable short-term.

Population

Healthy adults aged 20-65

Intervention

NMN 1,250 mg once daily orally for 4 weeks

Comparator

Placebo

Limitations

31 participants for only 4 weeks; funded by Mitsubishi Corporation Life Sciences, whose employees are authors; tolerability is not efficacy, and nothing was measured in joints. Full text read.